WOUNDCHEK Laboratories announced that it has received market clearance from Health Canada for WOUNDCHEK Protease Status, the world’s first point of care wound diagnostic for chronic wounds.

WOUNDCHEK Laboratories is currently looking for suitable distribution representation in Canada with the aim of achieving the necessary focus on the commercialisation of this innovative wound diagnostic product in the Canadian market.

The product will be presented at the Canadian Association of Wound Care (CAWC)’s annual conference in Toronto on October 31st, 2014, where WOUNDCHEK Laboratories will be exhibiting and expects much interest in the product from wound care practitioners in attendance.

It is anticipated that the product will be launched in the market by December 2014.

Jack Wilkens, CEO of WOUNDCHEK Laboratories, commented: "We are delighted with the news that our first product has been cleared for sale in Canada. Clinical trials aimed at gaining US FDA clearance of WOUNDCHEK™ Protease Status are currently underway, bringing us closer than ever to introducing wound diagnostics to the US market also."

He added: "Currently, the cost of ineffective treatment is estimated to be $20-25 billion annually. Our vision is to provide clinicians with accurate, timely, actionable, and easy to access information, leading to improved therapeutic outcomes and more cost effective care through point of care wound diagnostics."

WOUNDCHEK Protease Status, already available in Europe, the Middle East, and South Africa, detects elevated protease activity (EPA) in chronic wounds and was developed to help guide treatment decisions to enable improved outcomes and more cost effective care.